Cormorant Asset Management, LP 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Cormorant Asset Management, LP disclosed 50 US equity positions worth $2.0bn in its Q2 2026 13F filing. The largest position was PRAX at 11.0% of the reported book, followed by BBOT and PARABILIS MEDICINES INC. Against the Q1 2026 filing, it opened 13 new positions, added to 4 and reduced 28 among the top 50 holdings.
What did Cormorant Asset Management, LP own in Q2 2026? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 11.0% | $214.3m | 640,000 | -28% | reduced |
| 2 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 7.0% | $136.2m | 17,878,594 | 0% | held | |
| 3 | PARABILIS MEDICINES INC | 6.5% | $126.3m | 4,615,612 | – | new | |
| 4 | RAPP RAPPORT THERAPEUTICS INC | 5.7% | $110.7m | 2,657,521 | -10% | reduced | |
| 5 | ERAS ERASCA INC | Healthcare | 5.6% | $109.9m | 6,000,000 | 3% | added |
| 6 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 5.2% | $102.0m | 2,510,000 | -23% | reduced |
| 7 | EYPT EYEPOINT INC | Healthcare | 5.1% | $100.1m | 7,000,000 | -15% | reduced |
| 8 | ALMS ALUMIS INC | Healthcare | 4.7% | $92.5m | 3,285,596 | -17% | reduced |
| 9 | ABVX ABIVAX SA | Healthcare | 4.6% | $90.0m | 675,000 | -11% | reduced |
| 10 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 3.7% | $73.1m | 750,000 | -21% | reduced |
| 11 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 3.2% | $63.2m | 900,000 | -15% | reduced |
| 12 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 3.2% | $62.4m | 3,205,433 | -28% | reduced |
| 13 | BIOA BIOAGE LABS INC | 3.0% | $58.6m | 2,390,605 | -17% | reduced | |
| 14 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.6% | $50.8m | 533,340 | 0% | held |
| 15 | ANL ADLAI NORTYE LTD | 2.3% | $45.7m | 3,978,229 | 37% | added | |
| 16 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 2.1% | $41.0m | 550,000 | -35% | reduced |
| 17 | TNGX TANGO THERAPEUTICS INC | Healthcare | 2.1% | $40.6m | 1,300,000 | -9% | reduced |
| 18 | BHVN BIOHAVEN LTD | Healthcare | 2.0% | $38.8m | 2,610,000 | 48% | added |
| 19 | AGOMAB THERAPEUTICS NV | 1.6% | $32.0m | 2,465,348 | 0% | held | |
| 20 | MBX MBX BIOSCIENCES INC | Healthcare | 1.6% | $30.4m | 550,000 | -51% | reduced |
| 21 | CLYM CLIMB BIO INC | Healthcare | 1.4% | $27.5m | 2,106,000 | – | new |
| 22 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 1.4% | $26.9m | 2,150,000 | -45% | reduced |
| 23 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 1.3% | $26.0m | 1,000,000 | -34% | reduced |
| 24 | PHVS PHARVARIS N V | Healthcare | 1.3% | $25.9m | 750,000 | -25% | reduced |
| 25 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 1.1% | $22.0m | 2,344,971 | 0% | held |
| 26 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 1.0% | $20.0m | 225,000 | – | new |
| 27 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 1.0% | $18.8m | 400,000 | – | new |
| 28 | NEWAMSTERDAM PHARMA COMPANY | 0.9% | $16.9m | 500,000 | -47% | reduced | |
| 29 | ROIV ROIVANT SCIENCES LTD | Healthcare | 0.9% | $16.8m | 475,000 | -37% | reduced |
| 30 | CABA CABALETTA BIO INC | Healthcare | 0.8% | $15.6m | 5,000,000 | -9% | reduced |
| 31 | HELIX ACQUISITION CORP III | 0.7% | $13.8m | 1,297,500 | 0% | held | |
| 32 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.7% | $13.3m | 50,000 | – | new |
| 33 | KAILERA THERAPEUTICS INC | 0.6% | $12.1m | 550,000 | – | new | |
| 34 | INSM INSMED INC | Healthcare | 0.4% | $8.0m | 75,000 | -61% | reduced |
| 35 | FTH FAETH THERAPEUTICS INC | 0.4% | $7.7m | 1,028,242 | 236% | added | |
| 36 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.4% | $7.6m | 150,000 | – | new |
| 37 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 0.3% | $6.3m | 100,000 | -56% | reduced |
| 38 | IBIO IBIO INC | 0.3% | $6.2m | 3,570,000 | – | new | |
| 39 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 0.2% | $4.7m | 125,000 | -50% | reduced | |
| 40 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 0.2% | $4.6m | 175,000 | -61% | reduced |
| 41 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 0.2% | $4.1m | 50,000 | -50% | reduced |
| 42 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.2% | $4.0m | 75,000 | -57% | reduced |
| 43 | RESEARCH ALLIANCE CORP III | 0.2% | $4.0m | 370,000 | – | new | |
| 44 | COGT COGENT BIOSCIENCES INC | Healthcare | 0.2% | $3.9m | 100,000 | -50% | reduced |
| 45 | ALT ALTIMMUNE INC | Healthcare | 0.2% | $3.8m | 1,250,000 | – | new |
| 46 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 0.2% | $3.6m | 200,000 | -43% | reduced |
| 47 | ODYSSEY THERAPEUTICS INC | 0.2% | $3.3m | 175,000 | – | new | |
| 48 | PCVX VAXCYTE INC | Healthcare | 0.1% | $2.9m | 50,000 | -50% | reduced |
| 49 | BOLD BOUNDLESS BIO INC | 0.1% | $2.5m | 1,000,000 | – | new | |
| 50 | QUINCE THERAPEUTICS INC | 0.0% | $100.0k | 5,498 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.